US3794726A - Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one - Google Patents

Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one Download PDF

Info

Publication number
US3794726A
US3794726A US00282311A US3794726DA US3794726A US 3794726 A US3794726 A US 3794726A US 00282311 A US00282311 A US 00282311A US 3794726D A US3794726D A US 3794726DA US 3794726 A US3794726 A US 3794726A
Authority
US
United States
Prior art keywords
compound
benzotriazin
activity
chlorpromazine
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00282311A
Inventor
Z Ariyan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uniroyal Chemical Co Inc
Original Assignee
Uniroyal Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniroyal Inc filed Critical Uniroyal Inc
Application granted granted Critical
Publication of US3794726A publication Critical patent/US3794726A/en
Assigned to UNIROYAL CHEMICAL COMPANY, INC., WORLD HEADQUARTERS, MIDDLEBURY, CT. 06749, A CORP. OF NEW JERSEY reassignment UNIROYAL CHEMICAL COMPANY, INC., WORLD HEADQUARTERS, MIDDLEBURY, CT. 06749, A CORP. OF NEW JERSEY ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: UNIROYAL, INC., A NEW YORK CORP.
Assigned to UNIROYAL CHEMICAL COMPANY, INC. reassignment UNIROYAL CHEMICAL COMPANY, INC. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: UNIROYAL, INC., A NJ CORP.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Definitions

  • This compound has been found to be highly selective for the abolition of aggressive behavior at doses which cause little or no signs or symptoms of central nervous system depression or toxicity.
  • Chlorpromazine is a strong central nervous system (CNS) depressant, both in normal and schizophrenic patients. Its most salient feature, however, is the ability to inhibit aggressive behavior in abusive and destructive schizophrenics. It has been the drug of choice for the treatment of so-called back-ward schizophrenics, and is now used in out-patient therapy in cases of simple schizophrenia. The compounds have many sideeffects, the most serious of which is that it causes depression at the same time that it alleviates the schizophrenic symptoms. Incidentally, it also has a disadvantage in that it is quite toxic and has caused liver damage and blood disorders.
  • the abolition of aggressive behavior in schizophrenics without neurotoxicity, as characterized by depression, would be a most desirable feature for a new drug in the therapy of mental disease.
  • the compound of the present invention has been found to be an agent which selectively blocks aggressive behavior but which does not cause depression.
  • the invention is a method of treating aggressive behavior comprising administering a therapeutically effective dose of l,2,3-benzotriazin-4(3H)-one to an anxious animal.
  • 3,- 316,262 discloses that certain 3-substituted-l,2,3-benzotriazin-4(3H)-ones have antiphlogistic, antipyretic, analgesic, and sedative activity coupled with low toxicity. This patent does not, however, disclose antiaggression activity, i.e., the ability to selectively abolish aggressive behavior at doses which cause little or no signs or symptoms of CNS depression or toxicity.
  • 1,2,3-benzotriazin-4(3H)-one is disclosed as having sedative activity (but not anti-aggression activity), while benz-halogenated and 3-dialkyl-aminoalkyl analogs thereof were found to be devoid of pharmacological activity.
  • British Pat. No. 932,680 mentions a 3- aminobenzotriazinone N-carboxylic acid hydroxy-ethyl ester as a compound which possesses pronounced mus- .cle relaxing and analgesic activity.
  • U.S. Pat. No. 3,075,982 discloses certain derivatives as having valuable pharmaceutical properties as 1 i2$ -vc- 7.
  • U.S. Pat. No. 2,949,465 discloses 1,2,3-benzotriazin-4(3I-l)-one derivatives as plant fungicides.
  • U.S. Pat. No. 2,935,445 discloses trichloromethylthio derivatives as a nematocide.
  • U.S. Pat. No. 3,014,906 discloses 6-sulfamyl-3,7- disubstituted-l,2,3-benzotriazines as diuretics and for relief as pre-menstrual tension and similar periods of stress.
  • U.S. Pat. No. 3,471,489 discloses substituted l,2,3-benzotriazin-4(3H)-ones as useful insecticides, herbicides and central nervous system depressants.
  • British Pat. No. 1,110,265 discloses 3-phenyl 1,2,3-benzotriazin-4-ones as pharmacologically active compounds useful as sedative-hypnotics, anticonvulsants and hypoglycemics.
  • U.S. Pat. No. 3,492,406 discloses 3-(2- fluorophenyl)-1,2,3-benzotriazin-4-ones as an anorexigenic agent in mammals.
  • the present invention provides a method of inhibiting aggressive behavior in an anxious animal subject without causing the central nervous system depression which is a typical side effect of drugs heretofore used to treat aggressive behavior. This is achieved by administering to an anxious animal subject a therapeutically effective amount of l,2,3-benzotriazin-4(3H)-one, either as such, or in the form of a pharmaceutical composition including said compound.
  • the amount administered will be from about 2 to 100, preferably, from about 2 to 25 mg/kg/day of body weight.
  • the amount will be from about 0.03 to 1.4, preferably, from about 0.03 to 0.3 mg/kg/day of body weight.
  • the composition in the case of a tablet, will comprise, in addition to the active ingredient, fillers, binders and diluents such as lactose, methylcellulose, talc, gum tragacanth, gum acacia, agar, polyvinylpyrrolidone, stearic acid and/or corn starch.
  • a filler such as sodium carboxymethylcellulose and/or a syrup, e.g., a glycerine based syrup.
  • the most outstanding property of the compound of the present invention is the highly selective abolition of aggressive behavior in doses which cause little or no signs or symptoms of central nervous system depression or toxicity.
  • the compound can be classified as a psychotherapeutic agent, but it is unique in that no other agent of this class possesses the same spectrum of activity.
  • the compound of the present invention has a Neuropharmacological Profile [Samuel Irwin, Science 136,
  • lii'niice which rs eaisres that of the major tranquilizers such as chlorpromazine. It differs from chlorpromazine, however, in that it is a much weaker depressant of motor activity in the mouse. It was very active in inhibiting aggressive behavior in three models of experimental aggression; namely, isolated fighting behavior in mice, electroshock-induced fighting in mice, and septal rat aggression.
  • a major tranquilizer such as chlordiazepoxide
  • the compound of the present invention was found to be much more selective in inhibiting aggressive behavior than the latter. It does not possess significant anticonvulsant activity and in this respect it differs from chlordiazepoxide.
  • the compound of the present invention is orally active in mice and rats and orally is less toxic than chlorpromazine or chlordiazepoxide.
  • the compound of the present invention was studied in the Neuropharmacological Profile, which is a standardized multidimensional observation technique used on mice to grade symptomatology and acute toxicity relative to dosage.
  • the present compound In a dose range of 3-300 mg/kg, the present compound produced depression, reduced motor activity, hyporeflexia and hypothermia. A loss of righting occurred at the 300 mg/kg dose level and no convulsions were observed at any level. Depending on the dosage used, the onset of action varied between and 30 minutes and the effects lasted for approximately 30 minutes to several hours. The results of the Neuropharmacological Profile indicate that this compound is a central nervous system depressant having sedative properties.
  • mice or rats per dose were placed in individual photocell activity cages 30 minutes (mice) or 60 minutes (rats) after i.p. (intraperitoneal) administration of the drug, for a 30 minute activity count.
  • Table 1 shows the results obtained by comparing drug-treated groups with control activity. The SD being that dose causing a 50 percent reduction from control activity.
  • mice 140.0 mg/kg in mice and greater than 450 mg/kg in rats.
  • NTD is defined as the dose necessary to cause percent of mice or rats trained to walk a rotating wooden rod (5 rpm) to fall at the time of peak effect, and is a measure of drug effects on motor function or central nervous system toxicity.
  • Table II The results set forth in Table II were obtained when l,2,3-benzotriazin-4(3I-I)-one was tested against chlorpromazine and chlordiazepoxide.
  • the time of peak effect for each agent in both species was about 30-60 minutes after drug administration.
  • 1,2,3-benzotriazin-4('3H)-one was considerably less potent than either reference drug.
  • 1,2,3-benzotriazin-4(3I-I)-one appeared to be more centrally toxic in rats than in mice.
  • the compound of the present invention was compared with chlorpromazine and chlordiazepoxide for its anti-aggressive activity.
  • Four models of experimentallyinduced aggression in rodents were studied (RD. Sofia, Life Sciences 8: 705, 1969). The results of these experirnents are summarized in Table III.
  • the present compound is selectively active in blocking electroshock-induced fighting in mice; the ratio being 4.2 upon intraperitoneal injection. In this respect, it closely resembles chlordiazepoxide which gave a ratio of 3.3. Clorpromazine would be considered inactive in this respect since it did block electroshockinduced fighting, but only at neurotoxic doses.
  • Anti-convulsant activity was tested in the following procedures.
  • mice Groups of ten mice each were injected i.p. with a vehicle and the test drug and placed in individual plexiglas squares. Thirty minutes after i.p. injection, each mouse was administered an electric shock transcorneally at SOmA intensity, 0.2 seconds duration (Swinyard, et al., J. Pharmacol. Expzl. Ther. 106: 319, 1952). The criterion for activity is protection against tonic extension of the hind limbs. The dose necessary to protect 50 percent of the mice (MES-, was determined. The following results were obtained.
  • Cats were adminispresent invention shows potentiation of barbiturate antered the present compound at 20, 40 and 80 mg/kg esthesia. orally in capsule form and were observed continuously 2.
  • the (MOA) inhibitors are administered prior to the admin- Scoring System is the Same as that used in the mouse istration of DOPA, which is a noradrenaline precursor, p l A 20 and 40 g/kg h r w no signs or convulsions or excitation occur.
  • chlordiazepoxide has been shown depressant compouhds- Ah EDfifl in this test is defined by Baxter, Life Sciences, 3: 531, 1964, to increase the as that dose of test drug which Wiii cause the LD! (25 threshold of the hypothalamus to electrical stimulation.
  • chiorpmmazihe (10 mg/kg) chioi'di' cally plated in the perifornical region of the hypothalaaZepOXide mg/kg) was active in this test- Since mus, were used in this study.
  • Stimulation was accoml,2,3- n was hot Selectively plished in the unanesthetized, freely moving animal, live in the killer rat aggression test, which appears to and the threshold for the hissing response was deterdetect antidepressant activity it is Possih1e that this mined with the following stimulus parameters: square agent might Possess weak a a ah activity at wave stimulation of 150 Hz with a duration of 0.5 msec doses which cause neurotoxicity. Hence, a thii d test for and voltage ranging from 5.4 to 30. The present comdetection of anti-depressant activity was conducted. pound was administered orally in capsule form. The 4.
  • the stimulation threshold for Groups of mice were given 32 mg/kg of tetrabenazine the hiss response was determined at l, 2, 4, 6 and 24 intraperitoneally 30 minutes after injection of hours. If an effect was observed, the stimulation was 1,2,3-benzotriazin 4(3H)one (20 mg/kg). The degree carried out daily until the thresholds returned to conof ptosis (eyelid drooping or closure) was then deter- 0 trol values. The compound was administered in a dose mined exactly 30 minutes after tetrabenazine adminisrange of 20 to 40 mg/kg. Thecompound was studied in tration.
  • the compound of the present invention did not four implanted cats; two cats administered 20 mg/kg reverse tetrabenazine-induced ptosis as do the antideand two at 40 mg/kg.
  • the compound had no effect on pressants, desipramine or amitriptyline. hypothalamic stimulation at either dose.
  • the rage re- 5.
  • Oxotremorine Antagonism sponse was not changed in intensity of character and the delay from stimulus to response was not changed. A few measurements were made in an effort to establish if this compound decreased the threshold for the Cardiovascular Activity l,2,3-benzotriazin-4(3l-I)-one was also studied in the DOCA hypertensive rat, cardiovascular, and pharmacodynamic dog preparation.
  • the compound was administered to groups of five rats made hypertensive by the administration of desoxycorticosterone acetate and saline. Blood pressures were recorded 4 and 24 hours after oral administration of 25 and 100 mg/kg.
  • l,2,3-benzotriazin-4(3H)-one had no effect on the systolic blood pressure of the hypertensive rat at 25 mg/kg; however, at 100 mg/kg two out of five animals experienced a fall in blood pressure of 24 mm Hg at the four-hour observation period.
  • the apparent antihypertensive effect of the compound at the 100 mm/kg level is probably not significant, since it occurred at a dose twice that of the neurotoxic dose in rats.
  • the pharmacodynamic assay was performed using anesthetized dogs and recording blood pressure, electrocardiogram, and respiration. Responses to the fol- 25 lowing drugs were observed before and after the administration of l,2,3-benzotriazin-4(3H)-one, epinephrine, norepinephrine, dimethylphenylpiperazinium iodide (DMPP), acetylcholine, tyramine, and histamine.
  • DMPP dimethylphenylpiperazinium iodide
  • Table VIII gives the results of five day lethality stud- These data show that l,2,3-benzotriazin-4(3I-I)-one is less toxic than chlorpromazine, but more toxic than chlordiazepoxide when administered to mice; however, when administered to rats, it is less toxic than either of the two standard reference drugs.
  • the compound of the present invention may be administered to an anxious animal subject in any of a number of forms and via any of several routes.
  • the compound or compositions thereof may be orally administered in the form of tablets, pills, capsules, or in the form of a solution or liquid suspension. They may also be administered in the form of a parenteral suspension or solution.
  • the compound or compositions thereof may also be administered rectally, in the form of a suppository.
  • a tablet, pill or capsule consisting entirely of the desired compound, although ordinarily, a composition comprising an effective amount of the compound and varying amounts of one or more physiologically inert materials such as carriers, vehicles, binders and the like will be used. Additionally, the compounds may be orally administered in the form of a suspension thereof in a suitable vehicle such as a syrup.
  • parenterally administering the compound or compositions use may be made of a parenteral solution or suspension of the compound in a suitable solvent or suspension medium.
  • compositions of the present invention may also be administered rectally in the form of a suppository comprising an effective amount of the desired compound and a suitable vehicle such as petroleum jelly.
  • compositions according to the invention are specific formulations of compositions according to the invention:
  • EXAMPLE 1 Tablets may be prepared by the compression of a wet granulation containing the following:
  • a liquid suspension for oral administration may be prepared in the following formulation:
  • DFC Dry filled capsules
  • a parenteral suspension for intra-muscular administration may be prepared in the following formulation:
  • Dosage l suppository every 3 to 4 hours.
  • a method of inhibiting aggressive behavior in an anxious animal subject comprising administering to an anxious animal subject, an amount of l,2,3-benzotriazin-4(3H)-one which is effective to inhibit aggressive behavior in said animal subject without simultaneously causing depression.
  • said orally administrable dosage form is a pill, tablet, capsule, solution or suspension.
  • said effective amount is from about 2 to about mg/kg of body weight of said animal per day.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1,2,3-benzotriazin-4(3H)-one is useful as an anti-aggression agent.

Description

O United States Patent [1 1 [111 3,794,726 Ariyan Feb. 26, 1974 [5 INHIBITING AGGRESSIVE BEHAVIOR 3,471,489 lO/1969 Rigterink 424/249 W 1 2 3 3 3,652,560 3/1972 Livak 424/249 [75] Inventor: Zaven S. Ariyan, Woodbury, Conn. OTHER PUBLICATIONS [73] Assrgnee: Uniroyal, Inc., New York, NY. J. g Chem. vol. pp 613L615. [22] Filed: Aug. 21, 1972 [21] Appl. No.1 282,311 Primary Examiner-Stanley J. Friedman Attorney, Agent, or Firm-Willard R. Sprowls, Esq.
[52] US. Cl. 424/249 [51] Int. Cl A61k 27/00 581 Field of Search 424/249 [57] ABSTRACT 56] References Cited l,2,3-benzotr1azm-4(3H)-one 1s useful as an anti- UNITED STATES PATENTS 5/1960 Hosler et a]. 424/249 aggression agent.
11 Claims, No Drawings INHIBITING AGGRESSIVE BEHAVIOR WITH 1 ,2,3-BENZOTRIAZIN-( 3H)-ONE BACKGROUND OF THE INVENTION Form (A) is called 4-hydroxy-l,2,3-benzotriazine and form (B) is called l,2,3-benzotriazin-4( lH)-one.
This compound has been found to be highly selective for the abolition of aggressive behavior at doses which cause little or no signs or symptoms of central nervous system depression or toxicity.
It is well accepted in neuropharmacology that there is no clear distinction between sedative-hypnotics and minor tranquilizers. All known minor tranquilizers which are effective in reducing anxiety also produce drowziness, ataxia (inability to coordinate muscular movements) and sleep when given in larger doses. All sedative-hypnotic drugs in small doses are anxiolytic (causing apprehension or anxiety). Sedative hypnotics such as alcohol and short-acting barbiturates tend to produce behavioral excitation prior to promoting drowziness and sleep. The sedative-hypnotics and minor tranquilizers produce discrete, predictable changes in behavior that can be applied to therapeutic advantage in neurotics. Aside from their ability to promote sleep, their major behavioral action of therapeuitic advantage are their ability to slightly reduce the level of arousal-excitability, overcome passive avoidance (social withdrawal, suppressed or submissive) behavior, slightly diminish aggressive hostility, and increase the response to environmental stimuli. The effect, for example, of a psychomimetic (inducing psychosis like symptoms) drug on animal behavior such as LSD in rats and cats has been said to increase excitement and aggression.
Currently, aggressive behavior in mental disease patients is usually controlled by such major tranquilizers as chlorpromazine. This approach to the problem of controlling mental disorders is not entirely satisfactory since patients under the influence of this type of medication are overtly depressed and are not able to return satisfactorily to society and to function normally. Chlorpromazine is a strong central nervous system (CNS) depressant, both in normal and schizophrenic patients. Its most salient feature, however, is the ability to inhibit aggressive behavior in abusive and destructive schizophrenics. It has been the drug of choice for the treatment of so-called back-ward schizophrenics, and is now used in out-patient therapy in cases of simple schizophrenia. The compounds have many sideeffects, the most serious of which is that it causes depression at the same time that it alleviates the schizophrenic symptoms. Incidentally, it also has a disadvantage in that it is quite toxic and has caused liver damage and blood disorders.
The abolition of aggressive behavior in schizophrenics without neurotoxicity, as characterized by depression, would be a most desirable feature for a new drug in the therapy of mental disease. The compound of the present invention has been found to be an agent which selectively blocks aggressive behavior but which does not cause depression.
Accordingly, the invention is a method of treating aggressive behavior comprising administering a therapeutically effective dose of l,2,3-benzotriazin-4(3H)-one to an anxious animal.
2. Description of the Prior Art l,2,3-benzotriazin-4(3I-I)-one is a known compound which was first described in the chemical literature in 1887 by A. Weddige and H. Finger, Joum. fur prakt. Chem. [2], 35, 262 (1887); and H. Finger, Journ. fur prakt. Chem. [2], 37, 43l (1888) with no mention of any pharmaceutical activity.
Several methods for preparing this compound are known. These methods are summarized in the following reaction schemes:
f j E B \NEI NH dlazotlu II [Thlmlnlde] NH: N/ \l oxidation Hls Dlawtlul\ (alkaline KMnOO The above reaction schemes (1) to are described in the literature as follows:
(1) Weddige et al. J. pr. [2], 35, 262 (1887) Finger 1. pr. [2], 37, 432 (1888) (2) Zacharias .1. pr. [2], 43, 446 (1891) (3) 69, 103(1856) Thode Heller et al. J. pr. [2], 116, (1927) 1904 (4) Bamberger et a1. Ber. 31, 2637 (1898) Ann. 305, 359 (1899) (5) Reissert et a1. Ber. 42, 3710 (1909) There are many compounds that are similar to l ,2,3-benzotriazin-4( 3H)-one which are known to have pharmaceutical activity. For example, U.S. Pat. No. 3,- 316,262 discloses that certain 3-substituted-l,2,3-benzotriazin-4(3H)-ones have antiphlogistic, antipyretic, analgesic, and sedative activity coupled with low toxicity. This patent does not, however, disclose antiaggression activity, i.e., the ability to selectively abolish aggressive behavior at doses which cause little or no signs or symptoms of CNS depression or toxicity.
1n Shreekishna et al, J. Org. Chem. 26, 613 (1961), 1,2,3-benzotriazin-4(3H)-one is disclosed as having sedative activity (but not anti-aggression activity), while benz-halogenated and 3-dialkyl-aminoalkyl analogs thereof were found to be devoid of pharmacological activity.
Other references of interest are the following:
1. Cutting et al., Med. Pharmacol. Exptl. l5 (1), 7-16 (1966) which describes the present compound as being effective in decreasing the number of mice with litters by at least 50 percent.
2. Benzo-l,2,3-triazines" J. Org. Chem. 24, 272, 1959) discloses various derivatives of the present compound as possible pharmacologically active compounds.
3. A series of substituted derivatives of the present compound are reported in Gilmore et al., Journal Heterocyclic Chemistry 6, 809 (1969), and Stevens et al., J. Chem. Soc. (C) 765, (1970).
4. U.S. Pat. Nos. 2,758,115; 2,843,588; and 2,914,530, which disclose N-phosphate derivatives of the present compound as miticides and insecticides.
5. British Pat. No. 932,680 mentions a 3- aminobenzotriazinone N-carboxylic acid hydroxy-ethyl ester as a compound which possesses pronounced mus- .cle relaxing and analgesic activity.
6. U.S. Pat. No. 3,075,982 discloses certain derivatives as having valuable pharmaceutical properties as 1 i2$ -vc- 7. U.S. Pat. No. 2,949,465 discloses 1,2,3-benzotriazin-4(3I-l)-one derivatives as plant fungicides.
8. U.S. Pat. No. 2,935,445 discloses trichloromethylthio derivatives as a nematocide.
9. U.S. Pat. No. 3,014,906 discloses 6-sulfamyl-3,7- disubstituted-l,2,3-benzotriazines as diuretics and for relief as pre-menstrual tension and similar periods of stress.
10. U.S. Pat. No. 3,471,489 discloses substituted l,2,3-benzotriazin-4(3H)-ones as useful insecticides, herbicides and central nervous system depressants.
11. British Pat. No. 1,110,265 discloses 3-phenyl 1,2,3-benzotriazin-4-ones as pharmacologically active compounds useful as sedative-hypnotics, anticonvulsants and hypoglycemics.
l2. U.S. Pat. No. 3,492,406 discloses 3-(2- fluorophenyl)-1,2,3-benzotriazin-4-ones as an anorexigenic agent in mammals.
13. Netherland Pat. No. 6,702,189 discloses derivatives of the present compound as central nervous system depressants.
14. Netherland Pat. No. 6,603,319 discloses deriva tives of the present compound as having sedative activity and as being useful for treatment of psychoneurosis. The French equivalent is Pat. No. 1,552,801.
SUMMARY OF THE INVENTION The present invention provides a method of inhibiting aggressive behavior in an anxious animal subject without causing the central nervous system depression which is a typical side effect of drugs heretofore used to treat aggressive behavior. This is achieved by administering to an anxious animal subject a therapeutically effective amount of l,2,3-benzotriazin-4(3H)-one, either as such, or in the form of a pharmaceutical composition including said compound. Generally, the amount administered will be from about 2 to 100, preferably, from about 2 to 25 mg/kg/day of body weight. In humans, the amount will be from about 0.03 to 1.4, preferably, from about 0.03 to 0.3 mg/kg/day of body weight.
The pharmaceutical compositions which may be administered to an anxious animal subject in accordance with the invention comprise, in combination, a therapeutically effective amount of the compound of the present invention and a pharmaceutically acceptable carrier and/or diluent therefor.
For example, in the case of a tablet, the composition will comprise, in addition to the active ingredient, fillers, binders and diluents such as lactose, methylcellulose, talc, gum tragacanth, gum acacia, agar, polyvinylpyrrolidone, stearic acid and/or corn starch. In the case ofa liquid suspension for oral administration, the composition will comprise, in addition to the active ingredients, a filler such as sodium carboxymethylcellulose and/or a syrup, e.g., a glycerine based syrup.
DETAILED DESCRIPTION OF THE INVENTION The most outstanding property of the compound of the present invention is the highly selective abolition of aggressive behavior in doses which cause little or no signs or symptoms of central nervous system depression or toxicity. The compound can be classified as a psychotherapeutic agent, but it is unique in that no other agent of this class possesses the same spectrum of activity. The compound of the present invention has a Neuropharmacological Profile [Samuel Irwin, Science 136,
123 (1962)] lii'niice which rs eaisres that of the major tranquilizers such as chlorpromazine. It differs from chlorpromazine, however, in that it is a much weaker depressant of motor activity in the mouse. It was very active in inhibiting aggressive behavior in three models of experimental aggression; namely, isolated fighting behavior in mice, electroshock-induced fighting in mice, and septal rat aggression. In a comparative study with a major tranquilizer, such as chlordiazepoxide, the compound of the present invention was found to be much more selective in inhibiting aggressive behavior than the latter. It does not possess significant anticonvulsant activity and in this respect it differs from chlordiazepoxide. It does, however, cause a significant hypothermia which indicates an activity resembling chlorpromazine. and other major tranquilizers. It is a weak potentiator of pentobarbital and is inactive in the dl-dopa fighting test from monoamine oxidase inhibitors. It apparently does not possess anti-depressant activity since it did not reverse tetrabenazine ptosis. The compound of the present invention is orally active in mice and rats and orally is less toxic than chlorpromazine or chlordiazepoxide.
The compound of the present invention was studied in the Neuropharmacological Profile, which is a standardized multidimensional observation technique used on mice to grade symptomatology and acute toxicity relative to dosage.
In a dose range of 3-300 mg/kg, the present compound produced depression, reduced motor activity, hyporeflexia and hypothermia. A loss of righting occurred at the 300 mg/kg dose level and no convulsions were observed at any level. Depending on the dosage used, the onset of action varied between and 30 minutes and the effects lasted for approximately 30 minutes to several hours. The results of the Neuropharmacological Profile indicate that this compound is a central nervous system depressant having sedative properties.
The compound of the present invention and the two commonly used tranquilizers were subjected to the spontaneous locomotor activity test, in which six mice or rats per dose were placed in individual photocell activity cages 30 minutes (mice) or 60 minutes (rats) after i.p. (intraperitoneal) administration of the drug, for a 30 minute activity count. Table 1 shows the results obtained by comparing drug-treated groups with control activity. The SD being that dose causing a 50 percent reduction from control activity.
TABLE 1 Spontaneous Locomotor Activity LP. SD (mg/kg) MICE RATS 1,2,3-benzotriazin-4(3I-I)-one 44.0 82.5. chlorpromazine 2.8 1.7 Chlordiazepoxide 12.8 14.0
140.0 mg/kg in mice and greater than 450 mg/kg in rats.
In the neurotoxicity test, the value (NTD is defined as the dose necessary to cause percent of mice or rats trained to walk a rotating wooden rod (5 rpm) to fall at the time of peak effect, and is a measure of drug effects on motor function or central nervous system toxicity. The results set forth in Table II were obtained when l,2,3-benzotriazin-4(3I-I)-one was tested against chlorpromazine and chlordiazepoxide.
TABLE II Neurotoxicity NTD (mg/kg) Confidence Limits) LP. MICE 1,2,3-benzotriazin- 143.5 (99.1 207.0) 4(3H)-one chlorpromazine 0.7 (0.4 1.1) Chlordiazepoxide 13.8 (7.1 27.0)
1,2,3-benzotriazin- 320.0 (221.0 465.0) 4(3H)-one chlorpromazine 12.1 (8.5 17.3) Chlordiazepoxide 54.0 (38.6 75.6)
LP. RATS 1,2,3-benzotriazin- 55.5 (34.6 89.0) 4(3H)-one chlorpromazine 5.3 (3.1 9.1) Chlordiazcpoxide 4.3 (2.6 7.1)
P.O. 1,2,3-benzotriazin- 214.0 (110.0 415.0) 4(3H)-one Chlorpromazine 11.0 (6.1 19.9) Chlordiazepoxide 11.5 (8.8 15.1)
The time of peak effect for each agent in both species was about 30-60 minutes after drug administration.
Again, 1,2,3-benzotriazin-4('3H)-one was considerably less potent than either reference drug. In addition, 1,2,3-benzotriazin-4(3I-I)-one appeared to be more centrally toxic in rats than in mice.
The compound of the present invention was compared with chlorpromazine and chlordiazepoxide for its anti-aggressive activity. Four models of experimentallyinduced aggression in rodents were studied (RD. Sofia, Life Sciences 8: 705, 1969). The results of these experirnents are summarized in Table III.
TABLE III Anti-Aggressive Activity ED (95% Confidence Limits) (mg/kg) 1.P. P.O.
Agent ED... NTD /ED ED NTD ED Isolated Mouse Aggression 1.2,3-benzotriazin-4(3H)-one 6.7 (5.3-8.0) 21.7 17.0 (21.5-34.0) 18.8 Chlorpromazine 2.8 (2.0-3.9) 0.3 6.9 (5.1-9.4) 1.8 Chlordiuzepoxide 20.5 (11.3-37.5) 0.7 35.0 (25.4-48.3) 1.5
Electrnshock-lnduced Fighting in Mice l.2.3-henzotriazin-4(3H) one 34.0 (20.7-55.9) 4.2 Weakly Active (approx. mg/kg) chlorpromazine 5.5 (3.1-9.9) 0.1 0.86 (0.39-1.88) 14.0 Chlordiazepoxide 4 2 (2.3-7.7) 3.3 3.0 (1.7-5.4) 18.0
Septal Rat Aggression l,2,3-benzotriazin-4(3H)-one TABLE III AntiAggressive Activity ED (95% Confidence Limits) (mg/kg) I.P. P.O.
Agent ED NTD IED ED NTD ED l,2,3-benzotriazin-4(3H)-one 8.8 (4.4I7.6) 6.3 9.4 (4.7-l8.6) 22.8 Chlorpromazine 10.7 (4.525.7) 0.2 11.4 (6.l21.4) 0.9 Chlordiazepoxide 25.8 (14.0-47.5) 0.4 3.7 (13.0S9.0) 0.5
Killer Rat Aggression l,2,3-henzotriazin-4(3H)-one 85.0 (61.8 117.5) 0.65 Chlorpromazine 7.2 (4.3 11.8) 0.2 17.4 (10.1 29.8) 0.6 Chlordiazepoxide 36.3 (24.2 54.4) 0.3 74.0 (53.1 102.8) 0.2
When considering the results of these studies it should be understood that drug specificity is considered selective only when aggressive behavior is inhibited at doses which are significantly lower than those which impair rotarod performance (NTD or result in above criteria chlorpromazine and chlordiaz e poxide are considered non-selective in abolishing aggression in the isolated mouse and septal rat assays, since these drugs give ratios of less than 1. The present compound gives ratios of 6.3 and 21.7 in septa] rat and isolated mouse arrays when administered intraperitoneally, and 22.8 and 18.0 in the same assays when administered orally. These high ratios indicate a high degree of specificity for inhibiting experimentally-induced aggressive behavior. In addition, this degree of selectivity of the present compound for anti-aggressive activity is further supported by the fact that it is quite active at doses which are well below the doses inhibiting spontaneous locomotor activity. With respect to killer rat aggression, neither the present compound, chlorpromazine nor chlordiazepoxide were specific in inhibiting this type of aggression. This test is apparently selective for anti-depressants and stimulants, since reference agents from both these classes of drugs are selectively active (R.D. Sofia, Life Science, 8: 120, 1969).
The present compound is selectively active in blocking electroshock-induced fighting in mice; the ratio being 4.2 upon intraperitoneal injection. In this respect, it closely resembles chlordiazepoxide which gave a ratio of 3.3. Clorpromazine would be considered inactive in this respect since it did block electroshockinduced fighting, but only at neurotoxic doses.
Anti-convulsant activity was tested in the following procedures.
1. Maximal Electroshock Seizures (MES-,
Groups of ten mice each were injected i.p. with a vehicle and the test drug and placed in individual plexiglas squares. Thirty minutes after i.p. injection, each mouse was administered an electric shock transcorneally at SOmA intensity, 0.2 seconds duration (Swinyard, et al., J. Pharmacol. Expzl. Ther. 106: 319, 1952). The criterion for activity is protection against tonic extension of the hind limbs. The dose necessary to protect 50 percent of the mice (MES-, was determined. The following results were obtained.
TABLE IV aNTPn EDSQ rm of grsat st lae L Based on the Maximal Electroshock Seizures Agent I.P. MES mg/kg Inactive (100 mg/kg) Inactive (25 mg/kg) Chlorpromazine Chlordiazepoxide The present compound like chlorpromazine did not protect against MES even at very high doses. However, chlordiazepoxide did exhibit anti-convulsant activity. 2. Pentylenetetrazol Seizures (MET Seizures were produced in mice by subcutaneous administration of 125 mg/kg of pentylenetetrazol. The endpoints measured were convulsions and death. The dose necessary to protect 50 percent of the mice (MET for both parameters was determined. The following results were obtained.
TABLE V Pentylenetetrazol Seizures Agent l,2,3-benzotriazin-4( 3H )-one Chlorpromazine Chlordiazepoxide LP. MET mg/kg Inactive (200 mg/kg) Inactive (100 mg/kg) 7.] (5.6 for convulsions 2.6 (2.2 3.1) for death Of the drugs tested, only chlordiazepoxide exhibited antipentylenetetrazol activity.
Protection from d-amphetamine aggregationinduced lethality is usually afforded by alpha-adrenergic-blocking agents such as chlorpromazine, phenoxybenzamine, etc. Percent protection was determined for each compound and an ED value calculated. The results are summarized in Table VI.
TABLE VI d-Amphetamine Aggregation Agent ED mg/kg l,2,3-benzotriazin-4(3H )-one Inactive (50 200 mg/kg) Chlorpromazine 1.2 (0.8 1.8) Chlordiazepoxide Inactive (50 mg/kg) jection of sodium pentobarbital. This procedure detects compounds which possess analeptic or potentiating properties. The duration of sleeping time, as measured by loss of righting reflex, was determined. The
10 l,2,3-benzotriazin-4(3H)-one (100 mg/kg). Peripheral anti-cholinergic activity ,was assessed by inhibition of salivation, and central activity by inhibition of tremors. At 100 mg/kg, the present compound was completely Antagonism of the pharmacological effects of x0- tremorine, a potent cholinergic stimulant, was studied i i a er..- n r r tqn s a m nist s i v 9? results are presented as percent of control sleeping 5 devoid of any anti-cholinergic activity. time and are shown in Table VII. Neuropharmacological Profile Cat TABLE VI! Increase in Control Sleep Time l.P. Dose 1,2,3-benzolrimg/kg azin-4(3H)-one Chlorpromazine Chlordiazepoxide 0.5 124 L0 240 2.0 300 2.5 22 5. 7h 26 10.0 I32 43 20.0 159 40.0 I77 On a dose to dose relationship, the present com- 1,2,3-benzotriazin-4(3H)-one was studied in cats to pound appears to have approximately l/20th the podetermine the neuropharmacological effects as well as tency of chlorpromazine and twice the potency of the manner in which it is tolerated in cats. Neurotoxicchlordiazepoxide. Therefore, the compound of the ity was also evaluated in this assay. Cats were adminispresent invention shows potentiation of barbiturate antered the present compound at 20, 40 and 80 mg/kg esthesia. orally in capsule form and were observed continuously 2. Dihydroxyphenylalanine (dl-DOPA) Fighting Test for six hours using a standardized multidimensional ob- I i ll known h h monoamine id servation technique to grade symptomatology. The (MOA) inhibitors are administered prior to the admin- Scoring System is the Same as that used in the mouse istration of DOPA, which is a noradrenaline precursor, p l A 20 and 40 g/kg h r w no signs or convulsions or excitation occur. In this study, the MAO y p which pp to be g felatei The g inhibitor, pargyline, 0 /k a given 1 2 d 4 was well tolerated and no emesis occurred. At 80 hours prior to administering 200 mg/kg of dl-DOPA. "lg/kg the": was relaxation of the hiciiiaiihg Results of this experiment are manifested by excitation, r accompanied y ptosis and at and Six hour salivation, jumping and fighting. When 1,2,3-benzgtrigobservation the animals appeared depressed and a ten- Zin 4 (3H) one (60 140 mg/kg), chlorpromazine (5 dency for sleep was observed. No emesis occurred at mg/kg) or chlordiazepoxide 5 mg/kg) were adminis this dose and the animals appeared normal at 24 hours tered instead of parglyine, these symptoms were not f i 7 observed. This, in this procedure, none of the agents E k d fl th l i R Response C iesied 'f i to be inhibitors 40 The effect of the present compound on the hissing yohiihbihe poieiiiiaiioh response elicited by hypothalamic stimulation in cats poiehiiaiioh of ieihaiiiy induced by the alpha" was studied in an effort to determine if it had properties adiehei'gic blocking agent yohiihbihe, is considered to similar to that of chlordiazepoxide and other antibe a i'eiiabie Procedure to classify Possible ahii' anxiety-like agents. chlordiazepoxide has been shown depressant compouhds- Ah EDfifl in this test is defined by Baxter, Life Sciences, 3: 531, 1964, to increase the as that dose of test drug which Wiii cause the LD! (25 threshold of the hypothalamus to electrical stimulation. "lg/kg, -P- of yohhhbihe to be converted to the Cats with chronically implanted electrodes, stereotaxi- Vallle- Neither chiorpmmazihe (10 mg/kg) chioi'di' cally plated in the perifornical region of the hypothalaaZepOXide mg/kg) was active in this test- Since mus, were used in this study. Stimulation was accoml,2,3- n was hot Selectively plished in the unanesthetized, freely moving animal, live in the killer rat aggression test, which appears to and the threshold for the hissing response was deterdetect antidepressant activity it is Possih1e that this mined with the following stimulus parameters: square agent might Possess weak a a ah activity at wave stimulation of 150 Hz with a duration of 0.5 msec doses which cause neurotoxicity. Hence, a thii d test for and voltage ranging from 5.4 to 30. The present comdetection of anti-depressant activity was conducted. pound was administered orally in capsule form. The 4. Antagonism of Tetrabenazine-induced Ptosis present administration, the stimulation threshold for Groups of mice were given 32 mg/kg of tetrabenazine the hiss response was determined at l, 2, 4, 6 and 24 intraperitoneally 30 minutes after injection of hours. If an effect was observed, the stimulation was 1,2,3-benzotriazin 4(3H)one (20 mg/kg). The degree carried out daily until the thresholds returned to conof ptosis (eyelid drooping or closure) was then deter- 0 trol values. The compound was administered in a dose mined exactly 30 minutes after tetrabenazine adminisrange of 20 to 40 mg/kg. Thecompound was studied in tration. The compound of the present invention did not four implanted cats; two cats administered 20 mg/kg reverse tetrabenazine-induced ptosis as do the antideand two at 40 mg/kg. The compound had no effect on pressants, desipramine or amitriptyline. hypothalamic stimulation at either dose. The rage re- 5. Oxotremorine Antagonism sponse was not changed in intensity of character and the delay from stimulus to response was not changed. A few measurements were made in an effort to establish if this compound decreased the threshold for the Cardiovascular Activity l,2,3-benzotriazin-4(3l-I)-one was also studied in the DOCA hypertensive rat, cardiovascular, and pharmacodynamic dog preparation. The compound was administered to groups of five rats made hypertensive by the administration of desoxycorticosterone acetate and saline. Blood pressures were recorded 4 and 24 hours after oral administration of 25 and 100 mg/kg.
l,2,3-benzotriazin-4(3H)-one had no effect on the systolic blood pressure of the hypertensive rat at 25 mg/kg; however, at 100 mg/kg two out of five animals experienced a fall in blood pressure of 24 mm Hg at the four-hour observation period. The apparent antihypertensive effect of the compound at the 100 mm/kg level is probably not significant, since it occurred at a dose twice that of the neurotoxic dose in rats.
The pharmacodynamic assay was performed using anesthetized dogs and recording blood pressure, electrocardiogram, and respiration. Responses to the fol- 25 lowing drugs were observed before and after the administration of l,2,3-benzotriazin-4(3H)-one, epinephrine, norepinephrine, dimethylphenylpiperazinium iodide (DMPP), acetylcholine, tyramine, and histamine.
After 1 mg/kg i.v. of l,2,3-benzotriazin-4(3I-I)-one there was no change in blood pressure, electrocardiogram, respiration, or heart rate. Following the administration of 5 mg/kg i.v., there was a diminished response to the administration of epinephrine and norepinephrine; however, the response to the remaining challenging drugs were unchanged. An additional dose of 5 mg/kg i.v. caused a further suppression in epinephrine and norepinephrine responses; however, the other challenging drug responses were unchanged. Following an accumulative dose of l 1 mg/kg there was no effect on blood pressure, heart rate, or respiration. It is concluded that the present compound has no effect on the cardiovascular system with respect to the parameters measured, except that a weak alpha-adrenergic blocking activity was observed after 5 mg/kg i.v.
Table VIII gives the results of five day lethality stud- These data show that l,2,3-benzotriazin-4(3I-I)-one is less toxic than chlorpromazine, but more toxic than chlordiazepoxide when administered to mice; however, when administered to rats, it is less toxic than either of the two standard reference drugs.
The compound of the present invention, either alone or in the form of a pharmaceutical composition, may be administered to an anxious animal subject in any of a number of forms and via any of several routes. Thus, the compound or compositions thereof may be orally administered in the form of tablets, pills, capsules, or in the form of a solution or liquid suspension. They may also be administered in the form of a parenteral suspension or solution. The compound or compositions thereof may also be administered rectally, in the form of a suppository.
When orally administering the compound or compositions, use can be made of a tablet, pill or capsule consisting entirely of the desired compound, although ordinarily, a composition comprising an effective amount of the compound and varying amounts of one or more physiologically inert materials such as carriers, vehicles, binders and the like will be used. Additionally, the compounds may be orally administered in the form of a suspension thereof in a suitable vehicle such as a syrup.
When parenterally administering the compound or compositions, use may be made of a parenteral solution or suspension of the compound in a suitable solvent or suspension medium.
The compound and compositions of the present invention may also be administered rectally in the form of a suppository comprising an effective amount of the desired compound and a suitable vehicle such as petroleum jelly.
The following Examples are specific formulations of compositions according to the invention:
EXAMPLE 1 Tablets may be prepared by the compression of a wet granulation containing the following:
ies following single injections of a drug. All values pres- Ingredients In each ented represent tests conducted when animals were lLibenzmriazimflmm 20 mg housed ten per cage. l,2,3-ben2otr1azm-4(3I-I)-one lS po|yvinylpyno|idone 6 mg compared with chlorpromazine and chlordiazepoxide. Laclose 25 s- Alcohol, 3A, 200 proof 1 ml. In these and all the preceding calculations, the method Steam acid 3 mg of Litchfield and Wilcoxon (J. Pharmacol. Exptl. Ther. Talc 4 mg, 96: 99, 1949) was used to estimate effective (ED or Com Starch 15 sletha] (LDSO) dose Dosage: I Tablet 3 times a day.
TABLE VIII LD, Confidence Limits) mg/kg MICE RATS Agent LP. PD. LP. P.0.
|,2.3-henmtri- 273 440 423 S95 uzin-4(3H)-nne (239-3! I) (441-47!) (326-550) (4 l9-84l) Chlorpmmuzine I36 280 I37 357.7
(106-174) (187-418) (l33-l4l) 2377-5385) Chlordiazepoxide 400 810 265 392.l
EXAMPLE 2 A liquid suspension for oral administration may be prepared in the following formulation:
Dosage: l teaspoonful (5 cc.) every 4 to 6 hours.
EXAMPLE 3 Dry filled capsules (DFC) consisting of two sections of hard gelatin may be prepared from the following formulation:
Ingredients In each 1,2,3-benzotriazin-4(3H)-one 20 mg. Lactose USP q.s.
Dosage: l Capsule 3 times a day.
EXAMPLE 4 A parenteral suspension for intra-muscular administration may be prepared in the following formulation:
Ingredients In each l,2,3-bcnzotriazin-4(3H)-onc l mg. Isotonic solution (0.85% saline) 5 cc.
Surfactant (a 1% solution of polysorbate 80 USP) EXAMPLE 5 A suppository capsule formulated as below:
Dosage: l suppository every 3 to 4 hours.
I-Iaving thus described our invention, what we desire to claim and protect by letters patent is:
l. A method of inhibiting aggressive behavior in an anxious animal subject, said method comprising administering to an anxious animal subject, an amount of l,2,3-benzotriazin-4(3H)-one which is effective to inhibit aggressive behavior in said animal subject without simultaneously causing depression.
2. The method of claim 1, wherein said compound is administered in an orally administrable dosage form.
3. The method of claim 2, wherein said orally administrable dosage form is a pill, tablet, capsule, solution or suspension.
4. The method of claim 1, wherein said compound is administered in a parenterally administrable dosage form.
5. The method of claim 4, wherein said parenterally administrable dosage form is a solution or suspension.
6. The method of claim 1, wherein said compound is administered in a rectally administrable dosage form.
7. The method of claim 6, wherein said rectally administrable dosage form is a suppository.
8. The method of claim 1, wherein said effective amount is from about 2 to about mg/kg of body weight of said animal per day.
9. The method of claim 8, wherein said amount is from about 2 to about 25 mg/kg of body weight per day.
10. The method of claim 1, wherein said effective amount is from about 0.03 to about 1.4 mg/kg of body weight per day.
11. The method of claim 10, wherein said amount is from about 0.03 to about 0.3 mg/kg of body weight per day.

Claims (10)

  1. 2. The method of claim 1, wherein said compound is administered in an orally administrable dosage form.
  2. 3. The method of claim 2, wherein said orally administrable dosage form is a pill, tablet, capsule, solution or suspension.
  3. 4. The method of claim 1, wherein said compound is administered in a parenterally administrable dosage form.
  4. 5. The method of claim 4, wherein said parenterally administrable dosage form is a solution or suspension.
  5. 6. The method of claim 1, wherein said compound is administered in a rectally administrable dosage form.
  6. 7. The method of claim 6, wherein said rectally administrable dosage form is a suppository.
  7. 8. The method of claim 1, wherein said effective amount is from about 2 to about 100 mg/kg of body weight of said animal per day.
  8. 9. The method of claim 8, wherein said amount is from about 2 to about 25 mg/kg of body weight per day.
  9. 10. The method of claim 1, wherein said effective amount is from about 0.03 to about 1.4 mg/kg of body weight per day.
  10. 11. The method of claim 10, wherein said amount is from about 0.03 to about 0.3 mg/kg of body weight per day.
US00282311A 1972-08-21 1972-08-21 Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one Expired - Lifetime US3794726A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28231172A 1972-08-21 1972-08-21

Publications (1)

Publication Number Publication Date
US3794726A true US3794726A (en) 1974-02-26

Family

ID=23080926

Family Applications (1)

Application Number Title Priority Date Filing Date
US00282311A Expired - Lifetime US3794726A (en) 1972-08-21 1972-08-21 Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one

Country Status (4)

Country Link
US (1) US3794726A (en)
DE (1) DE2336586A1 (en)
FR (1) FR2196806A1 (en)
GB (1) GB1422745A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234925A (en) * 1991-08-14 1993-08-10 Dana-Farber Cancer Institute, Inc. 2-aza-2-desamino analogues of 5,8-dideazafolic acid
WO2016081736A1 (en) * 2014-11-20 2016-05-26 Takeda Pharmaceutical Company Limited 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
US12370192B2 (en) 2019-09-16 2025-07-29 Takeda Pharmaceutical Company Limited Azole-fused pyridazin-3(2H)-one derivatives
US12559465B2 (en) 2020-05-08 2026-02-24 Takeda Pharmaceutical Company Limited Substituted benzotriazinone metabolites of a GPR139 agonist

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2935445A (en) * 1957-11-21 1960-05-03 American Cyanamid Co Nu-trichloromethylthio-1, 2, 3-benzotriazine-4-one as a novel nematocide
US3471489A (en) * 1968-07-29 1969-10-07 Dow Chemical Co 1,2,3-benzotriazin-4(3h)-ones
US3652560A (en) * 1970-06-18 1972-03-28 Dow Chemical Co 3-((alkylthio)methyl)-1 2 3-benzotriazin-4(3h)-ones

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2935445A (en) * 1957-11-21 1960-05-03 American Cyanamid Co Nu-trichloromethylthio-1, 2, 3-benzotriazine-4-one as a novel nematocide
US3471489A (en) * 1968-07-29 1969-10-07 Dow Chemical Co 1,2,3-benzotriazin-4(3h)-ones
US3652560A (en) * 1970-06-18 1972-03-28 Dow Chemical Co 3-((alkylthio)methyl)-1 2 3-benzotriazin-4(3h)-ones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Org. Chem., Vol. 26, (1961), pp. 613 615. *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234925A (en) * 1991-08-14 1993-08-10 Dana-Farber Cancer Institute, Inc. 2-aza-2-desamino analogues of 5,8-dideazafolic acid
WO2016081736A1 (en) * 2014-11-20 2016-05-26 Takeda Pharmaceutical Company Limited 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
US9556130B2 (en) 2014-11-20 2017-01-31 Takeda Pharmaceutical Company Limited 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
KR20170084324A (en) * 2014-11-20 2017-07-19 다케다 야쿠힌 고교 가부시키가이샤 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
CN107108531A (en) * 2014-11-20 2017-08-29 武田药品工业株式会社 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of GPR139
US9770450B2 (en) 2014-11-20 2017-09-26 Takeda Pharmaceutical Company Limited 4-OXO-3,4-dihydro-1,2,3-benzotriazine as modulators of GPR139
US10159677B2 (en) 2014-11-20 2018-12-25 Takeda Pharmaceutical Company Limited 4-OXO-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
EP3536324A1 (en) * 2014-11-20 2019-09-11 Takeda Pharmaceutical Company Limited 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
EA033728B1 (en) * 2014-11-20 2019-11-20 Takeda Pharmaceuticals Co 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
US10561662B2 (en) 2014-11-20 2020-02-18 Takeda Pharmaceutical Company Limited 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
CN107108531B (en) * 2014-11-20 2020-10-20 武田药品工业株式会社 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of GPR139
CN112062730A (en) * 2014-11-20 2020-12-11 武田药品工业株式会社 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of GPR139
US11173161B2 (en) 2014-11-20 2021-11-16 Takeda Pharmaceutical Company Limited 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
CN112062730B (en) * 2014-11-20 2023-09-29 武田药品工业株式会社 4-oxo-3, 4-dihydro-1, 2, 3-benzotriazines as modulators of GPR139
US12370192B2 (en) 2019-09-16 2025-07-29 Takeda Pharmaceutical Company Limited Azole-fused pyridazin-3(2H)-one derivatives
US12559465B2 (en) 2020-05-08 2026-02-24 Takeda Pharmaceutical Company Limited Substituted benzotriazinone metabolites of a GPR139 agonist

Also Published As

Publication number Publication date
DE2336586A1 (en) 1974-02-28
GB1422745A (en) 1976-01-28
FR2196806A1 (en) 1974-03-22

Similar Documents

Publication Publication Date Title
ES2348999T3 (en) TIADIAZOL DERIVATIVES FOR THE TREATMENT OF NEURODEGERATIVE DISEASES.
EA012502B1 (en) Melanocortin receptor-specific compounds
US3923833A (en) N-{8 (1-cyano-2-phenyl)ethyl{9 carbamates
DE3435745A1 (en) 2- (3- (4- (3-PHENYL) -1-PIPERAZINYL) PROPYL) -2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ON COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, AND CONTAINING THESE COMPOUNDS PHARMACEUTICAL AGENTS
JP2002053566A (en) Thiazole compound and pharmaceutical use thereof
US3892777A (en) Substituted benzylethylenedicarbamates
US3794726A (en) Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
US20050136444A1 (en) Treating neuropathic pain with neuropeptide FF receptor 2 agonists
US3821384A (en) Pharmaceutical compositions containing a4-aryl-2-(3-pyridyl)thiazole and methods of using same
US3000903A (en) Phenylalkylhydrazines and use as psychotherapeutics
HU219458B (en) 2-Phenyl-3,5-dimethylmorpholine derivatives, pharmaceutical compositions containing them, and methods for their preparation
JP2865255B2 (en) 1,2,3,4,10,14b-Hexahydrodibenzo [c, f] pyrazino [1,2-a] azepino derivatives and 10-aza, 10-oxa and 10-thia analogs
DE69731658T2 (en) THE USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MOTION FLUCTUATIONS
JPS627182B2 (en)
DE69426620T2 (en) ANTIDEPRESSIVA
KR20230159996A (en) Novel oxadiazole derivative compounds and pharmaceutical composition for preventing and treating neuroinflammatory disease comprising the same
US3879531A (en) 2-aminothiazoles compositions and methods for using them as psychotherapeutic agents
FR2464256A1 (en) 4-PHENYL AND 5-PHENYL DERIVATIVES OF 1,4,5,6-TETRAHYDROPYRIMIDINES, PROCESS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THEIR APPLICATION TO THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
FR2480285A1 (en) 2- (3- (4- (3-CHLORO-4-FLUOROPHENYL) -1-PIPERAZINYL) PROPYL) -1,2,4-TRIAZOLO (4,3-A) PYRIDIN-3 (2H) -ONE; PREPARATION AND PHARMACEUTICAL COMPOSITIONS
WO2017129061A1 (en) Application of substituted cinnamamide derivatives in preparation of anti-anxiety medications
GB2093450A (en) 2,1,3-benzothiadiazole derivatives
Bova et al. Norbormide: a calcium entry blocker with selective vasoconstrictor activity in rat peripheral arteries
IE51791B1 (en) Pharmaceutical compositions effective against coronary heart disease and hypertension
US3842172A (en) Pharmaceutical compositions containing a 4-substituted-2-(3-pyridyl)thiazole and methods of using same
US3790600A (en) 2-(3-benzo(b)thenyl)-2-thiopseudourea and its pharmaceutically acceptable salts

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIROYAL CHEMICAL COMPANY, INC., WORLD HEADQUARTER

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:UNIROYAL, INC., A NEW YORK CORP.;REEL/FRAME:004488/0204

Effective date: 19851027

AS Assignment

Owner name: UNIROYAL CHEMICAL COMPANY, INC., WORLD HEADQUARTER

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST. EFFECTIVE DATE OCTOBER 27, 1985.;ASSIGNOR:UNIROYAL, INC., A NJ CORP.;REEL/FRAME:004754/0186

Effective date: 19870130